CVAC
CureVac N.V.

6,464
Mkt Cap
$1.16B
Volume
367,915.00
52W High
$5.72
52W Low
$2.48
PE Ratio
7.18
CVAC Fundamentals
Price
$5.14
Prev Close
$5.16
Open
$5.16
50D MA
$5.32
Beta
1.02
Avg. Volume
1.36M
EPS (Annual)
$0.7819
P/B
1.14
Rev/Employee
$588,910.74
Loading...
Loading...
News
all
press releases
Carlson Capital L.P. Makes New Investment in CureVac N.V. $CVAC
Carlson Capital L.P. bought a new position in CureVac N.V. (NASDAQ:CVAC - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
CureVac (NASDAQ:CVAC) Sees Large Volume Increase - Here's What Happened
CureVac (NASDAQ:CVAC) Sees Large Volume Increase - Still a Buy...
MarketBeat·7d ago
News Placeholder
Company News for Nov 25, 2025
Companies In The News Are: CVAC, CAAP, NVO, BABA.
Zacks·9d ago
News Placeholder
CureVac N.V. (NASDAQ:CVAC) Given Consensus Rating of "Hold" by Brokerages
Shares of CureVac N.V. (NASDAQ:CVAC - Get Free Report) have been given an average rating of "Hold" by the six analysts that are presently covering the stock, MarketBeat.com reports. Five research...
MarketBeat·11d ago
News Placeholder
Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates
Immatics (IMTX) delivered earnings and revenue surprises of +2.00% and -50.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
News Placeholder
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of -12.50% and +1.69%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
Quinn Opportunity Partners LLC Acquires 204,073 Shares of CureVac N.V. $CVAC
Quinn Opportunity Partners LLC grew its stake in CureVac N.V. (NASDAQ:CVAC - Free Report) by 305.3% during the second quarter, according to the company in its most recent filing with the Securities...
MarketBeat·20d ago
News Placeholder
Amphastar Pharmaceuticals (AMPH) Q3 Earnings and Revenues Top Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of +20.78% and +3.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·28d ago
News Placeholder
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Beats Revenue Estimates
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +19.35% and +1.12%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·29d ago
News Placeholder
Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Oncobiologics (OTLK) delivered earnings and revenue surprises of -4.76% and -40.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago

Latest CVAC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.